The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients

Keyphrases

• Adjuvant Therapy 100%
• Ipilimumab 100%
• Melanoma Patients 100%
• High-risk Melanoma 100%
• Interferon-α (IFN-α) 50%
• Melanoma 50%
• Completion Lymph Node Dissection 50%
• Advanced Melanoma 50%
• Effective Treatment 25%
• Clinical Decision-making 25%
• Cancer Treatment 25%
• 5-year Survival 25%
• Phase II Trial 25%
• Prognostic Information 25%
• High Dose 25%
• Placebo 25%
• Individual Patient Data Meta-analysis 25%
• Spectacular 25%
• Active Substances 25%
• Highly Effective 25%
• Cancer Clinical Trials 25%
• European Organizations 25%
• Trametinib 25%
• Sentinel 25%
• Toxicity Profile 25%
• Sentinel Lymph Node 25%
• Dabrafenib 25%
• Neoadjuvant Setting 25%
• Pembrolizumab 25%
• Neoadjuvant 25%
• Nivolumab 25%
• Number of Positive Nodes 25%
• Practice Changing 25%
• Overall Survival Benefit 25%
• BRAF mutant 25%
• Anti-PD1 Agents 25%
• Combined Method 25%

Medicine and Dentistry

• Adjuvant Therapy 100%
• Melanoma 100%
• Ipilimumab 57%
• Retroperitoneal Lymph Node Dissection 28%
• Interferon 28%
• Survival Rate 14%
• Overall Survival 14%
• Clinical Decision Making 14%
• Meta-Analysis 14%
• Cancer Treatment 14%
• Drug Megadose 14%
• Patient-Data 14%
• Placebo 14%
• Trametinib 14%
• Pembrolizumab 14%
• Nivolumab 14%
• Dabrafenib 14%
• Sentinel Lymph Node 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Melanoma 100%
• Ipilimumab 57%
• Interferon 28%
• Malignant Neoplasm 14%
• Overall Survival 14%
• Survival Rate 14%
• Placebo 14%
• Pembrolizumab 14%
• Nivolumab 14%
• Dabrafenib 14%
• Trametinib 14%